Baven­cio from Mer­ck KGaA, Pfiz­er en­coun­ters yet an­oth­er tri­al set­back

Just when Baven­cio’s prospects were be­gin­ning to look a lit­tle brighter af­ter pos­i­tive con­fir­ma­to­ry tri­al read­out in Jan­u­ary, the ther­a­py has fiz­zled in an­oth­er on­col­o­gy in­di­ca­tion.

The late-stage 697-pa­tient tri­al was test­ing the use of Baven­cio in com­bi­na­tion with chemora­dio­ther­a­py (CRT) against stan­dard-of-care CRT in pa­tients with un­treat­ed, lo­cal­ly-ad­vanced squa­mous cell car­ci­no­ma of the head and neck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER